Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma-Reference-Cited by-同舟云学术

Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma

Published:2020-06 Issue:3 Volume:4 Page:e398
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:

Author:

Hess Georg,Wagner Karola,Keller Ulrich,La Rosee Paul,Atta Johannes,Hübel Kai,Lerchenmueller Christian,Schoendube Daniel,Witzens-Harig Mathias,Ruckes Christian,Medler Christoph,van Oordt Christina,Klapper Wolfram,Theobald Matthias,Dreyling Martin

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hematology

Reference50 articles.

1. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG);Buske;Leukemia.,2009

2. Treatment of older patients with mantle-cell lymphoma;Kluin-Nelemans;N Engl J Med.,2012

3. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies;Rule;Br J Haematol.,2017

4. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Dreyling;Ann Oncol.,2017

5. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer;Hidalgo;Clin Cancer Res.,2006

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of mTOR in B Cell Lymphoid Malignancies: Biologic and Therapeutic Aspects;International Journal of Molecular Sciences;2023-09-14

2. Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimus;Hematological Oncology;2023-06-10

3. Clinical Experiences with Drugs Targeting m TOR;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

4. Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents;European Journal of Medicinal Chemistry;2023-01

5. The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients;Cancers;2022-03-18